Although most older adults support Medicare coverage of medications for weight loss drugs, only one in three favor paying more in premiums for this coverage, finds University of Michigan survey.
In the United States, more than 40% of people are affected by obesity and unless the obesity stems from a preexisting condition, Medicare is prohibited from covering drugs strictly for weight loss due to a Medicare Part D law passed in 2003.
However, 76% of adults in the United States are in favor of Medicare coverage for weight management, according to the National Poll for Healthy Aging, published by the University of Michigan.
Researchers asked roughly 2,700 adults ages 50 to 80 about their weight, how they managed it and their views on Medicare coverage of weight loss drugs such as Wegovy and Zepbound, which have experienced a 300% increase in demand, CNBC reports.
Almost three-quarters of respondents reported that they had been overweight at some point in their lives. In addition, 92% had tried at least one method to lose weight, with exercise being the most common choice at 89%. Of the people who had never taken a drug strictly for weight loss, 59% said they would be interested in taking one in the future.
“Expanding access to a range of weight management treatments can lead to improvements in health and potentially lower costs,” the authors write. “Many weight loss medications are very expensive, resulting in high potential out-of-pocket costs.”
For example, without coverage, a 30-day supply of Ozempic currently costs around $950, according to GoodRx.
Additional weight loss strategies participants were in favor of covering were dietician sessions (83%), weight loss surgery (73), and gym memberships (65%).
The results of the University of Michigan study were published December 2023. The research was conducted in July and August.
This story was first published on Managed Healthcare Executive.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More